227 related articles for article (PubMed ID: 12789294)
21. Immunity to cancer through immune recognition of altered self: studies with melanoma.
Guevara-Patiño JA; Turk MJ; Wolchok JD; Houghton AN
Adv Cancer Res; 2003; 90():157-77. PubMed ID: 14710950
[TBL] [Abstract][Full Text] [Related]
22. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
24. Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma.
Zwicker K; Chatten C; Gratton K; Demetrick D; Serra P; Shameli A; Santamaria P; Bathe OF
J Immunol; 2009 Aug; 183(3):1705-14. PubMed ID: 19570832
[TBL] [Abstract][Full Text] [Related]
25. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
26. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
27. A role for innate immunity in type 1 diabetes?
Beyan H; Buckley LR; Yousaf N; Londei M; Leslie RD
Diabetes Metab Res Rev; 2003; 19(2):89-100. PubMed ID: 12673777
[TBL] [Abstract][Full Text] [Related]
28. The role of innate immune responses in autoimmune disease development.
Waldner H
Autoimmun Rev; 2009 Mar; 8(5):400-4. PubMed ID: 19162250
[TBL] [Abstract][Full Text] [Related]
29. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
30. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
31. The human T cell response to melanoma antigens.
Romero P; Cerottini JC; Speiser DE
Adv Immunol; 2006; 92():187-224. PubMed ID: 17145305
[TBL] [Abstract][Full Text] [Related]
32. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
33. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
34. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
36. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells.
Parmiani G
Immunol Today; 1993 Nov; 14(11):536-8. PubMed ID: 8274196
[TBL] [Abstract][Full Text] [Related]
37. Effector immune mechanisms in cancer.
Lotzová E
Nat Immun Cell Growth Regul; 1985; 4(6):293-304. PubMed ID: 3911064
[No Abstract] [Full Text] [Related]
38. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
Höfs T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
[TBL] [Abstract][Full Text] [Related]
39. Vaccines against advanced melanoma.
Blanchard T; Srivastava PK; Duan F
Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
[TBL] [Abstract][Full Text] [Related]
40. The immune system: cells and molecules for the integration of self and non-self.
Eichmann K
Int J Sports Med; 1991 Jun; 12 Suppl 1():S2-4. PubMed ID: 1894393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
